Datavault AI Inc. (NASDAQ: DVLT) has expanded its definitive licensing agreement with DataMeds AI Inc. (NASDAQ: MEDS) to extend its PharmacyChain blockchain-related technology beyond pharmaceutical distribution into commercial healthcare, healthspan and wellness applications. The expanded relationship is designed to support patient-controlled health data access, monetization and real-world asset tokenization across pharmacy, medical, laboratory and wearable device environments.
According to the announcement, the agreement leverages a behavioral healthcare patent portfolio focused on medical logistics, IoT population health and AI-driven remote patient monitoring. Under the amended terms, Datavault AI will receive common shares representing approximately 19.9% of DataMEDS’ outstanding common stock upon closing of previously announced related transactions, replacing the preferred shares originally contemplated for tax optimization purposes.
The companies said the agreement accelerates deployment of Datavault AI’s technology into the healthcare sector, targeting opportunities within the rapidly expanding global health and wellness market while enabling new patient-controlled data transaction models. This move signals a strategic pivot toward empowering individuals with ownership and control over their health data, a growing trend in the digital health space.
Datavault AI’s cloud-based platform provides comprehensive solutions with a collaborative focus in its Acoustic Sciences and Data Sciences divisions. The Data Science division leverages Web 3.0 and high-performance computing to provide solutions for experiential data perception, valuation and secure monetization. The company’s technology suite is fully customizable and offers AI- and machine-learning-based automation, third-party integration, detailed analytics and data, marketing automation and advertising monitoring.
The expanded agreement has implications for the healthcare industry by potentially reducing administrative burdens and enabling new revenue streams for patients through data monetization. For the broader market, it highlights the growing intersection of blockchain, AI and healthcare, which could reshape how medical data is managed and exchanged. Investors should note that Datavault AI will hold a significant equity stake in DataMEDS, aligning incentives for both companies to succeed in the commercial healthcare space.
For more details, the full press release is available at https://ibn.fm/vBAxH. Additional information about Datavault AI can be found at https://dvlt.ai.
